Monistat 3 leads OTC vaginal yeast infection market with sales of $64.4 mil. -- IRI.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL MONISTAT 3 LEADS VAGINAL YEAST INFECTION MARKET with sales in food, drug and mass market channels of $64.4 mil., up 4.5% in the 52 weeks ended May 24, according to data from Chicago-based Information Resources, Inc. Monistat 7 had higher unit sales than the three-day product -- 5.3 mil. units -- but lower dollar sales ($56.7 mil.), reflecting the seven-day product's lower retail price ($9-$12 versus $13-$16). Monistat 7's dollar sales were down 10.1% from the comparable period the year before, and unit sales fell 5.2%. Both products contain 2% miconazole.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning